XORTX Therapeutics (XORTX Therapeutics) EPS (Diluted) : $-3.62 (TTM As of Sep. 2023)

View and export this data going back to 2018. Start your Free Trial

What is XORTX Therapeutics EPS (Diluted)?

XORTX Therapeutics's Earnings per Share (Diluted) for the three months ended in Sep. 2023 was $-0.67. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was $-3.62.

XORTX Therapeutics's EPS (Basic) for the three months ended in Sep. 2023 was $-0.67. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2023 was $-3.62.

XORTX Therapeutics's EPS without NRI for the three months ended in Sep. 2023 was $-0.67. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2023 was $-3.83.

During the past 3 years, the average EPS without NRIGrowth Rate was -104.60% per year. During the past 5 years, the average EPS without NRI Growth Rate was -35.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 8 years, XORTX Therapeutics's highest 3-Year average EPS without NRI Growth Rate was 21.40% per year. The lowest was -104.60% per year. And the median was -21.60% per year.

XORTX Therapeutics EPS (Diluted) Historical Data

The historical data trend for XORTX Therapeutics's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XORTX Therapeutics EPS (Diluted) Chart

XORTX Therapeutics Annual Data

Trend

Feb15

Feb16

Feb17

Dec18

Dec19

Dec20

Dec21

Dec22

EPS (Diluted)

Get a 7-Day Free Trial

-4.66

-0.83

-1.34

-1.20

-4.71

XORTX Therapeutics Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
EPS (Diluted)	Get a 7-Day Free Trial															-0.83	-1.15	-0.99	-0.81	-0.67

Competitive Comparison of XORTX Therapeutics's EPS (Diluted)

For the Biotechnology subindustry, XORTX Therapeutics's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

XORTX Therapeutics's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, XORTX Therapeutics's PE Ratio distribution charts can be found below:

* The bar in red indicates where XORTX Therapeutics's PE Ratio falls into.

XORTX Therapeutics EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

XORTX Therapeutics's Diluted EPS for the fiscal year that ended in Dec. 2022 is calculated as

Diluted EPS (A: Dec. 2022 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-6.989	-	0)	/	1.480
	=	-4.72

XORTX Therapeutics's Diluted EPS for the quarter that ended in Sep. 2023 is calculated as

Diluted EPS (Q: Sep. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-1.333	-	0)	/	1.999
	=	-0.67

EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.62

XORTX Therapeutics (NAS:XRTX) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

XORTX Therapeutics EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of XORTX Therapeutics's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

XORTX Therapeutics (XORTX Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XORTX Therapeutics Inc (NAS:XRTX) » Definitions » EPS (Diluted)

Comparable Companies

Traded in Other Exchanges

ANUA:Germany XRTX:Canada

Address

3710 - 33rd Street NW, Calgary, AB, CAN, T2L 2M1

Website

https://www.xortx.com

XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.